Top 3 Health Care Stocks That Are Preparing To Pump This Month - Exact Sciences ( NASDAQ:EXAS ) , Outset Medical ( NASDAQ:OM )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
Why Is Insulet Peer Tandem Diabetes Stock Trading Lower Today - Tandem Diabetes Care ( NASDAQ:TNDM )
Tandem posts a Q2 loss of $0.78 vs. $0.40 estimate; the stock plunges due to guidance cuts and device recalls. 700 adverse events and 59 injuries linked to malfunctioning insulin pumps trigger medical device correction. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy ...
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Tandem Diabetes Care, Inc. ( TNDM ) Reports Q2 Loss, Beats Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -20.00% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Bears are Losing Control Over Tandem Diabetes Care ( TNDM ) , Here's Why It's a 'Buy' Now
Tandem Diabetes Care (TNDM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential ...
Neuronetics ( STIM ) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of -87.50% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Stereotaxis Inc. ( STXS ) Report Negative Earnings Next Week? What You Should Know
Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care, Inc. ( TNDM ) Expected to Beat Earnings Estimates: Should You Buy?
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care ( TNDM )
The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Aehr Test System ( NASDAQ:AEHR ) , Bit Digital ( NASDAQ:BTBT )
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Aehr Test Systems, Inc. AEHR fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter sales results.
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Medtronic Is Separating Its Diabetes Business - Good News For Investors - Medtronic ( NYSE:MDT )
Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction - an initial minority IPO carve-out followed by a split-off of the remaining stake.
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Beta Bionics ( NASDAQ:BBNX ) , Insulet ( NASDAQ:PODD ) , DexCom ( NASDAQ:DXCM )
Goldman sets $380 target for Insulet, citing Omnipod's unique design and share capture potential. Dexcom gets $104 target, expected to gain share in non-insulin diabetes segments through 2025. Rebound or breakdown? See how Matt Maley is trading June's market volatility, live this Wednesday, June ...
Does This Move Make Medtronic Stock a Buy?
Over the past few years, Medtronic ( NYSE: MDT ) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its ...
Tandem Diabetes Care ( TNDM ) Up 6.5% Since Last Earnings Report: Can It Continue?
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
Tandem Diabetes Care, Inc. ( TNDM ) Reports Q1 Loss, Tops Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -11.67% and 6.44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What to Expect From These 3 MedTech Stocks This Earnings Season?
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
Penumbra ( PEN ) Q1 Earnings and Revenues Top Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 25.76% and 2.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Hold TNDM Stock in Your Portfolio for Now
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.
2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction
With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares of top companies on the dip. It's a great strategy, but it's essential to avoid those companies that only look undervalued but actually aren't.Some stocks are lagging the ...
Tandem Diabetes Care ( TNDM ) Moves 7.6% Higher: Will This Strength Last?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Boston Scientific ( NYSE:BSX ) , DexCom ( NASDAQ:DXCM )
Pharmaceuticals, which accounted for $200 billion in U.S. imports in 2024, are exempt from the 10% global tariff. Diabetes device makers face tariff-related pressures, while larger cardiac and orthopedic device firms are expected to adapt. With stocks plunging, steady income is key.
Tandem Diabetes Care ( TNDM ) Down 8.9% Since Last Earnings Report: Can It Rebound?
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.
Reasons to Hold TNDM Stock in Your Portfolio for Now
A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.
This H.B. Fuller Company Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Beyond ( NYSE:BYON ) , CubeSmart ( NYSE:CUBE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Bernie McTernan downgraded Beyond, Inc.
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.
Tandem Diabetes Care, Inc. ( TNDM ) Reports Q4 Loss, Lags Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -76% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care ( TNDM ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
NeuroPace ( NPCE ) Surges 5.8%: Is This an Indication of Further Gains?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tactile Systems Technology ( TCMD ) Tops Q4 Earnings and Revenue Estimates
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 21.21% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Infusion Devices Market to Reach US$ 23.08 Billion by 2031, Driven by Rising Prevalence of Infectious Diseases
US & Canada, Jan. 24, 2025 ( GLOBE NEWSWIRE ) -- According to a comprehensive report from The Insight Partners, "Infusion Devices Market Size and Forecast ( 2021 - 2031 ) , Global and Regional Share, Trend, and Growth Opportunity Analysis Report" The infusion devices market is expected to reach ...
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?
TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.
Is SPDR S&P Health Care Equipment ETF ( XHE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if it's a buy or hold for your portfolio!
Reasons to Retain TNDM Stock in Your Portfolio for Now
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.
Inari Medical ( NARI ) Soars 30.6%: Is Further Upside Left in the Stock?
Inari Medical (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
Tandem Diabetes Care ( TNDM ) Down 9.2% Since Last Earnings Report: Can It Rebound?
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain TNDM Stock in Your Portfolio for Now
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Baxter Intl ( NYSE:BAX ) , DexCom ( NASDAQ:DXCM )
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to "Attractive," believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care, Inc. ( TNDM ) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 16.28% and 9.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. ( DCTH ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Delcath Systems, Inc. ( DCTH ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Tandem Diabetes Care, Inc. ( TNDM ) to Report a Decline in Earnings: What to Look Out for
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
